
Themis Medicare (THEMISMED) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
717.0M
Gross Profit
511.1M
71.29%
Operating Income
-83.2M
-11.60%
Net Income
-96.6M
-13.48%
Balance Sheet Metrics
Total Assets
5.9B
Total Liabilities
1.9B
Shareholders Equity
4.0B
Debt to Equity
0.46
Cash Flow Metrics
Revenue & Profitability Trend
Themis Medicare Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 4.1B | 3.8B | 3.4B | 3.9B | 2.3B |
Cost of Goods Sold | 1.3B | 1.4B | 1.2B | 1.5B | 805.3M |
Gross Profit | 2.7B | 2.4B | 2.2B | 2.4B | 1.5B |
Gross Margin % | 67.5% | 62.9% | 64.9% | 61.2% | 64.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 332.6M | 263.7M | 278.5M | 161.6M |
Other Operating Expenses | 1.3B | 726.6M | 715.5M | 661.8M | 436.6M |
Total Operating Expenses | 1.3B | 1.1B | 979.2M | 940.3M | 598.2M |
Operating Income | 391.2M | 392.6M | 569.6M | 861.6M | 409.5M |
Operating Margin % | 9.6% | 10.4% | 16.5% | 22.0% | 17.9% |
Non-Operating Items | |||||
Interest Income | - | 8.4M | 5.5M | 6.1M | 4.1M |
Interest Expense | 100.4M | 76.3M | 79.9M | 65.4M | 109.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 396.7M | 534.4M | 725.1M | 952.6M | 413.3M |
Income Tax | 98.4M | 99.2M | 156.1M | 223.8M | 56.3M |
Effective Tax Rate % | 24.8% | 18.6% | 21.5% | 23.5% | 13.6% |
Net Income | 298.3M | 435.2M | 569.0M | 728.8M | 357.0M |
Net Margin % | 7.4% | 11.6% | 16.5% | 18.6% | 15.6% |
Key Metrics | |||||
EBITDA | 596.4M | 732.3M | 909.5M | 1.1B | 608.2M |
EPS (Basic) | ₹3.24 | ₹4.73 | ₹6.18 | ₹7.92 | ₹3.89 |
EPS (Diluted) | ₹3.24 | ₹4.72 | ₹6.17 | ₹7.91 | ₹3.88 |
Basic Shares Outstanding | 92077160 | 92040120 | 92027700 | 92002700 | 91884540 |
Diluted Shares Outstanding | 92077160 | 92040120 | 92027700 | 92002700 | 91884540 |
Income Statement Trend
Themis Medicare Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 65.6M | 99.2M | 125.5M | 202.8M | 190.2M |
Short-term Investments | 124.9M | 144.8M | 112.6M | 111.6M | 109.4M |
Accounts Receivable | 1.8B | 1.8B | 1.5B | 1.0B | 776.1M |
Inventory | 843.1M | 705.7M | 689.5M | 608.1M | 584.9M |
Other Current Assets | 234.0M | 10.5M | 10.5M | 10.5M | 10.9M |
Total Current Assets | 3.0B | 2.9B | 2.6B | 2.1B | 1.9B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.7B | 54.7M | 52.6M | 51.3M | 50.1M |
Goodwill | 3.3M | 5.5M | 7.7M | 9.9M | 12.1M |
Intangible Assets | - | 5.5M | 7.7M | 9.9M | 12.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 133.4M | 124.6M | 142.6M | 89.3M | -54.0K |
Total Non-Current Assets | 2.8B | 2.7B | 2.5B | 2.1B | 1.9B |
Total Assets | 5.9B | 5.7B | 5.1B | 4.3B | 3.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 514.4M | 472.9M | 400.4M | 318.7M | 307.9M |
Short-term Debt | 643.8M | 690.2M | 639.3M | 554.3M | 638.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 11.3M | 43.0M | 44.3M | 40.3M | 41.8M |
Total Current Liabilities | 1.6B | 1.5B | 1.4B | 1.1B | 1.3B |
Non-Current Liabilities | |||||
Long-term Debt | 186.1M | 267.7M | 284.5M | 243.0M | 233.8M |
Deferred Tax Liabilities | 88.3M | 73.9M | 69.4M | 64.7M | 9.5M |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 293.1M | 341.7M | 353.9M | 307.7M | 243.3M |
Total Liabilities | 1.9B | 1.9B | 1.7B | 1.4B | 1.5B |
Equity | |||||
Common Stock | 92.1M | 92.0M | 92.0M | 92.0M | 91.9M |
Retained Earnings | - | 2.3B | 1.9B | 1.4B | 717.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.0B | 3.8B | 3.4B | 2.9B | 2.2B |
Key Metrics | |||||
Total Debt | 829.9M | 957.9M | 923.8M | 797.3M | 871.8M |
Working Capital | 1.5B | 1.4B | 1.3B | 1.0B | 571.6M |
Balance Sheet Composition
Themis Medicare Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 396.7M | 534.4M | 725.1M | 952.6M | 413.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -99.4M | -288.0M | -490.0M | -435.8M | 71.0M |
Operating Cash Flow | 382.2M | 322.7M | 315.1M | 582.2M | 594.0M |
Investing Activities | |||||
Capital Expenditures | -137.4M | -183.9M | -287.1M | -193.0M | -179.9M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | 0 | 0 | 0 | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -137.4M | -183.9M | -287.1M | -193.0M | -179.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -46.0M | -46.0M | -46.0M | -39.6M | -16.1M |
Debt Issuance | - | - | - | - | 72.6M |
Debt Repayment | - | - | - | - | -196.9M |
Financing Cash Flow | -92.4M | 9.5M | 43.3M | -118.5M | -276.7M |
Free Cash Flow | 192.8M | 36.8M | -126.6M | 137.7M | 389.4M |
Net Change in Cash | 152.3M | 148.2M | 71.2M | 270.7M | 137.3M |
Cash Flow Trend
Themis Medicare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
32.38
Price to Book
2.46
Price to Sales
2.60
PEG Ratio
-1.03
Profitability Ratios
Profit Margin
-2.39%
Operating Margin
-12.95%
Return on Equity
7.41%
Return on Assets
5.07%
Financial Health
Current Ratio
1.95
Debt to Equity
20.61
Beta
-0.22
Per Share Data
EPS (TTM)
₹-0.99
Book Value per Share
₹43.74
Revenue per Share
₹41.26
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
themismed | 9.9B | 32.38 | 2.46 | 7.41% | -2.39% | 20.61 |
Sun Pharmaceutical | 3.8T | 36.65 | 5.28 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 68.71 | 10.59 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 46.4B | -13.50 | -21.28 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.6B | 23.66 | 3.26 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.5B | 202.31 | 6.17 | 4.35% | 1.41% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.